“The pharmaceutical sector brings forward economic value, social impact and human capital activation. Working on a ’Life science strategy’ can create Italy’s attractiveness”. This was stated in Bari during the presentation of a study by The European House Ambrosetti by Claudio Longo, President and CEO of astrazeneca in Italy.
What strategies are being implemented to enhance biopharmaceutical innovation in Italy?
Interview with Claudio Longo, President and CEO of AstraZeneca Italy: The Future of the Pharmaceutical Sector in Italy
Time.news Editor (TNE): Claudio, thank you for joining us today.You recently presented a significant study by The European House Ambrosetti in Bari. Can you elaborate on the concept of a “Life Science Strategy” and its significance for italy?
Claudio Longo (CL): Thank you for having me. The “Life Science Strategy” is pivotal for enhancing Italy’s attractiveness on the global stage in biopharmaceutical innovation. By focusing on economic value, social impact, and activating human capital, we can foster an ecosystem that supports research and advancement, ultimately benefiting public health and driving economic growth.
TNE: That sounds promising! What are some of the key economic benefits associated with strengthening the pharmaceutical sector in Italy?
CL: Strengthening the pharmaceutical sector can lead to job creation, increased investments in research, and improved patient outcomes.When we attract top-tier talent and resources, we can innovate more effectively, which contributes to Italy’s competitiveness in the global market. The study highlights that a robust pharmaceutical industry not only drives local economies but also creates ripple effects in healthcare delivery and public welfare.
TNE: You mentioned the social impact of the pharmaceutical sector. Can you share some insights into how this impacts communities?
CL: Absolutely. A thriving pharmaceutical industry leads to better access to medicines and healthcare solutions. It also fosters collaborations between academia, government, and private sectors to tackle pressing health challenges. The social obligation we adopt allows us to not only treat illnesses but also invest in preventative measures, thereby enhancing the quality of life for communities across Italy.
TNE: What practical advice woudl you give to stakeholders in the pharmaceutical industry looking to contribute to this Life Science Strategy?
CL: Collaboration is key. stakeholders must engage in partnerships, leverage technology, and invest in training the next generation of professionals. We should also advocate for policies that support innovation and streamline the regulatory surroundings. Continuous dialog between industry leaders, policymakers, and academic institutions can facilitate creating a more attractive landscape for biopharmaceutical development.
TNE: Lastly, how do you see the future of the pharmaceutical sector evolving in Italy over the next decade?
CL: I expect to see significant advancements in personalized medicine and biotechnology. With a committed approach to our Life Science Strategy, Italy can become a leader in innovative therapies and solutions.If we maintain our focus on economic and social value, we can transform our pharmaceutical landscape into one that is not only beneficial for Italy but also for the global community.
TNE: Thank you,Claudio,for your valuable insights. It’s clear that the pharmaceutical sector holds a promising future for Italy, and we look forward to witnessing its evolution.
CL: Thank you for the opportunity.It’s an exciting time for our industry!
